Nektar Therapeutics (NKTR) Work In Process (2011 - 2024)

Nektar Therapeutics (NKTR) posted quarterly Work In Process of $10.6 million for Q2 2024, up 6.3% quarter-over-quarter from $10.0 million in Q1 2024.

Nektar Therapeutics (NKTR) Work In Process (2011 - 2024) Analysis & Trends

Nektar Therapeutics' Work In Process history runs 12 years deep, the most recent figure standing at $10.6 million for Q2 2024.

In Q2 2024, Work In Process changed N/A year-over-year to $10.6 million; the TTM figure through Jun 2024 stood at $10.6 million (changed N/A YoY), while the FY2023 annual figure was $12.9 million, up 19.83% from the prior year.
Work In Process for Q2 2024 stood at $10.6 million, up from $10.0 million in the prior quarter.
The five-year high for Work In Process was $12.9 million in Q4 2023, with the low at $10.0 million in Q1 2024.
The 3-year median for Work In Process is $10.7 million (2022), against an average of $11.3 million.
Peak annual rise in Work In Process reached 19.83% in 2023, while the deepest fall reached 19.83% in 2023.
Nektar Therapeutics' Work In Process stood at $10.7 million in 2022, then climbed by 19.83% to $12.9 million in 2023, then declined by 17.78% to $10.6 million in 2024.
Business Quant data shows NKTR's Work In Process at $10.6 million in Q2 2024, $10.0 million in Q1 2024, and $12.9 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Nektar Therapeutics	1.49 Bn	919.46 Mn	3.16 Mn

Download Data